Drs Ursula A. Matulonis and Mansoor Mirza discuss immunotherapy trials, novel therapies such as CDK4/6 inhibitors and antibody-drug conjugates, and shared decision-making.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999852. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/

Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial https://pubmed.ncbi.nlm.nih.gov/37864337/

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) https://pubmed.ncbi.nlm.nih.gov/33078978/

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/37669480/

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/